GSK To Pay $3B To Settle US Avandia, Medicaid Probes

Law360, New York (November 3, 2011, 12:29 PM EDT) -- GlaxoSmithKline PLC has agreed to pay $3 billion to settle criminal and civil investigations by the U.S. government, including probes into its marketing of a controversial diabetes drug and possible abuses of Medicaid's rebate program, the drug giant said Thursday.

The settlement, which will be finalized in 2012, will end a probe by the U.S. Attorney's Office for the District of Massachusetts into GSK's marketing practices, as well as the U.S. Department of Justice's investigations into possible violations tied to Medicaid's rebate program and into the...
To view the full article, register now.